1 tic target, not only for asthma but also for hypersecretory airway diseases.

2 ade may provide effective new treatments for hypersecretory airway diseases.

3 out asthma to assess if asthmatic cells were hypersecretory and determined whether the underlying mec

4 cells cultured from subjects with asthma are hypersecretory compared with cells from healthy donors a

5 roles for inhibitors of the EGF-R cascade in hypersecretory diseases of airways.

6 plasia is a critical pathological feature in hypersecretory diseases of airways.

7 osal gland hypertrophy are shared with other hypersecretory diseases, such as chronic obstructive pul

8 provide new therapeutic approaches in airway hypersecretory diseases.

9 h should lead to the rational design of anti-hypersecretory drugs for treatment of airway mucus hyper

10 ingly, human CLCA1 is a critical mediator of hypersecretory lung diseases, such as asthma, chronic ob

11 hophysiology of asthma impact upon the mucus hypersecretory phenotype.

12 thermore, asthma might have a specific mucus hypersecretory phenotype.

13 te in a positive feedback loop involving the hypersecretory response.

14 or Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every